Bispecific mAbs consist of two various parts of mAbs, e.g., blinatumomab, bounded to CD3 and CD19 and are applied for treating acute lymphocytic leukemia (ALL) (99). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.